Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Short-Term Debt repayments (2017 - 2025)

Myriad Genetics (MYGN) has disclosed Short-Term Debt repayments for 7 consecutive years, with $60.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Short-Term Debt repayments rose 200.0% to $60.0 million in Q3 2025 year-over-year; TTM through Dec 2025 was $80.5 million, a 32.64% decrease, with the full-year FY2025 number at $80.5 million, down 32.64% from a year prior.
  • Short-Term Debt repayments was $60.0 million for Q3 2025 at Myriad Genetics, up from $20.5 million in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of $106.4 million in Q3 2021 to a low of $19.5 million in Q4 2024.
  • A 4-year average of $46.6 million and a median of $45.0 million in 2021 define the central range for Short-Term Debt repayments.
  • Biggest YoY gain for Short-Term Debt repayments was 200.0% in 2025; the steepest drop was 65.83% in 2025.
  • Myriad Genetics' Short-Term Debt repayments stood at $106.4 million in 2021, then crashed by 62.41% to $40.0 million in 2023, then plummeted by 51.25% to $19.5 million in 2024, then skyrocketed by 207.69% to $60.0 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Short-Term Debt repayments are $60.0 million (Q3 2025), $20.5 million (Q1 2025), and $19.5 million (Q4 2024).